Order Shield™

Barriers to
CRC Screening Blood-Based CRC
Screening Guardant Health’s
Legacy Guardant
Access FAQs Resources Blog Employers Request Info

Our Shield™ blood test gains FDA approval, ushering in a new era of colorectal cancer screening. More details

03/14/2024

A cell-free DNA blood-based test for colorectal cancer screening

ECLIPSE validates Shield as an accurate screening method for CRC

Back to Blog Listing

Sign up to receive the latest updates on Shield^TM

Email address

Please enter a valid email address.

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.

Guardant Health press release ECLIPSE trial on ClinicalTrials.gov

Compliance

in real-world clinical settings for colorectal cancer (CRC) screening¹*

Proven accuracy in the pivotal ECLIPSE^† trial, with 83% sensitivity and 90% specificity^2‡§

One of the largest studies and first of its kind to validate a blood test that detects CRC³

The future of CRC screening starts now. Go

*Compliance rate for the first 8,000 patients that were prescribed Shield and completed it.¹

^†The ECLIPSE study (NCT04136002) compared to the sensitivity and specificity of cfDNA - only Shield with findings from subsequent colonoscopy in over 20,000 average-risk patients.^1,2
^‡Specificity detected for advanced neoplasia defined in ECLIPSE as CRC or advanced adenomas.^1,3
^§Patients had no prior diagnosis of CRC, inflammatory bowel disease, or family history of genetic risk for CRC (eg, Lynch syndrome).³

References: 1. Data on file. Guardant Health, Inc. 2. Guardant Health press release. December 15, 2022. 3. ECLIPSE trial on ClinicalTrials.gov

Share this page:

A cell-free DNA blood-based test for colorectal cancer screening

Sign up to receive the latest updates on ShieldTM

Sign up to receive the latest updates on Shield^TM